Telisotuzumab Vedotin For Injection 20 mg, 100 mg Suppliers & Bulk Manufacturers

Available Forms: Lyophilised powder vial (IV infusion)

Available Strengths: 20 mg, 100 mg

Reference Brands: Emrelis (AbbVie)

Category: Oncology Cancer Care

Telisotuzumab vedotin (Emrelis, AbbVie) is an antibody-drug conjugate against c-Met for previously treated non-small cell lung cancer with high c-Met protein levels, granted accelerated approval by the US FDA in May 2025. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Product Description:

Telisotuzumab vedotin is an antibody-drug conjugate. Its antibody binds c-Met, a growth-factor receptor that is overexpressed on some lung cancers, and delivers the cell-killing agent monomethyl auristatin E (MMAE) into those cells. It is the first treatment approved specifically for c-Met protein overexpression, which is different from the MET exon 14 mutation targeted by capmatinib and tepotinib.

The US FDA granted accelerated approval as Emrelis in May 2025 for adults with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression who have had prior systemic therapy. A tissue test confirms c-Met levels before treatment. It is given by intravenous infusion every two weeks from 20 mg and 100 mg powder vials; nerve damage (peripheral neuropathy) is a common side effect.

Sourcing and licensing notes. Telisotuzumab vedotin is patented and made only by AbbVie; there is no biosimilar. We confirm registration status for each destination before quoting.